LCD-L39481
Document details
Summary
The implementation of the MolDX guidelines for molecular biomarker testing in rheumatoid arthritis could significantly affect billing processes related to targeted therapy. Providers will need to ensuNew billing guidelines for rheumatoid arthritis testing effective 2025.
Affected codes
ICD-10-CM
Affected specialty
Rheumatology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39481&ver=8CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761458 · Rheumatology
This newly approved drug, EXDENSUR (Depemokimab), has a confirmed route of administration as subcutaneous injection, allowing billing teams to categorize it under Part B. As it aligns with injectable
View alertPolicy LCD-L39427 · Rheumatology
The MolDX policy for molecular biomarker testing could significantly impact reimbursement for targeted therapy selection in Rheumatoid Arthritis. As this policy becomes effective, providers may need t
View alertPolicy LCD-L39467 · Rheumatology
The new LCD for Molecular Biomarker Testing in Rheumatoid Arthritis may expand the coverage for specific biomarkers, improving the choice of targeted therapies. This change will allow practices to bil
View alertPolicy LCD-L39469 · Rheumatology
The implementation of the MolDX guidelines for molecular biomarker testing in rheumatoid arthritis will ensure more precise targeting of therapies and could enhance treatment outcomes. As these guidel
View alert